Results 71 to 80 of about 19,821,917 (190)

Beyond Gut Modulation: A Critical Review of the Therapeutic Potential, Safety, and Clinical Prospects of Natural Polysaccharides for IBD

Food Safety and Health, EarlyView.
In this review, we critically summarized the application of natural polysaccharides (NPs) for the treatment of IBD. This approach combines, in a unique way (right), the basic structure–activity relationships of NPs from different origins (left) with their multipronged mode of action, which involves modulation of the gut microbiota and other ...
Felix Danso, A. M. Abd El‐Aty, Kwaku Amoah, Xianghong Ju   +3 more
wiley   +1 more source

Non-vitamin K antagonist oral anticoagulants therapy for atrial fibrillation patients undergoing electrophysiologic procedures [PDF]

, 2020
Over the last 10 years since the introduction of non-vitamin K antagonist oral anticoagulants (NOACs) into routine clinical practice our experience with these drugs has increased tremendously, also in the context of patients undergoing electrophysiology ...
Steffel, Jan
core   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation

Anatolian Journal of Cardiology, 2019
Non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), who had malignant disease.
Anetta Undas, Leszek Drabik
doaj   +1 more source

Bioactive Natural Products in Cardiovascular Disease: Focus on Thrombotic Events

Phytotherapy Research, EarlyView.
An overview of the role of natural products (NP) in cardiovascular disease prevention, highlighting key mechanisms of action: including antiplatelet, antithrombotic, anti‐inflammatory, and antioxidant effects. Additionally, it illustrates the integration of diet–drug interactions, nutritional epigenetics, and the role of artificial intelligence in ...
Maria Nektaria Magkoulia, Despoina Pantazi   +1 more
wiley   +1 more source

Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients

Transplantology, 2022
The use of novel oral anticoagulants in patients with impaired renal function or undergoing immunosuppressive therapy is limited due to the risk of drug-to-drug interactions and anticoagulation-related adverse events.
Mikołaj Młyński, Mikołaj Sajek, Zbigniew Heleniak, Alicja Dębska-Ślizień   +3 more
doaj   +1 more source

Pericapsular nerve group block with phenol for non‐operative hip fracture management in patients living with frailty: a prospective multicentre cohort study

Anaesthesia, EarlyView.
Summary Introduction The incidence of hip fractures is rising with the ageing population. For patients living with severe frailty and limited life expectancy, non‐operative management is increasingly considered after shared decision‐making. Given the limited availability of long‐term analgesic options, alternative techniques are needed.
Rachel J. H. Smits, Marte I. Lommerse, Hugo H. Wijnen, Lennart G. Wasmoeth, Glenn van de Vossenberg, Gezina T. M. L. Oei, Henk J. Schuijt, Kris C. P. Vissers, Hanna C. Willems, Jan Willem Kallewaard, Selina E. I. van der Wal, the Dutch‐PENG registry collaborators, Gert R. Roukema, Dawi Van der Stap, J.S.H.A. (Seppe) Koopman, Bart P.A. Spaetgens, Renée Brüggemann, Nicole Lefel, Manon Vugts, Nikki M.F. Noorda, Vincent Van Dongen, Hidde Krot, Nicole Grupa, Daisy Hoofwijk, Léon Timmerman   +24 more
wiley   +1 more source

Pulmonary Embolism—A Century of Progress

ANZ Journal of Surgery, EarlyView.
Reviews a century of progress in the diagnosis, prevention, and management of pulmonary embolism; from the first successful surgical embolectomy in 1924 to advanced imaging, pharmacological thromboprophylaxis, and treatment. In the 21st century, advances include catheter‐directed thrombolysis or mechanical thrombectomy under decision‐making guidance of
D. A. Watters
wiley   +1 more source

To investigate the rates and contributing factors to adverse drug events for patients treated with non-vitamin K antagonist oral anticoagulants versus warfarin, a vitamin K antagonist

, 2021
An adverse drug event (ADE) for this thesis is defined as harm from a medication resulting in hospitalisation. Oral anticoagulants are among the most common drugs worldwide which contribute to medication-related ADEs.
Kerry Louise Watts (20168229)
core  

Genetic determinants of response and adverse effects following vitamin K antagonist oral anticoagulants [PDF]

, 2017
Background: Vitamin K antagonist anticoagulants (warfarin/acenocoumarol) are commonly used anticoagulants that require careful clinical management to balance the risks of over anticoagulation and bleeding with those of under anticoagulation and clotting.
P. V., Dattatreya, R., Rashmi, S., Parameshwar   +2 more
core   +1 more source